Tiziana Life Sciences is trading at $0.64, up +6.62%, with no confirmed company-specific catalyst identified during the November 6, 2026 session. - On November 5, the company announced a November 9 investor call to discuss positive Phase 2a INFORM-MS results; available coverage does not establish the announcement as the cause of the move. - Broader signals were mixed: major U.S. indices were mostly higher, while supplied biotech-sector context showed XBI down 5.19%. The move’s driver remains unclear.